176 related articles for article (PubMed ID: 16236930)
1. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension.
Bonderman D; Nowotny R; Skoro-Sajer N; Jakowitsch J; Adlbrecht C; Klepetko W; Lang IM
Chest; 2005 Oct; 128(4):2599-603. PubMed ID: 16236930
[TBL] [Abstract][Full Text] [Related]
2. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial.
Jaïs X; D'Armini AM; Jansa P; Torbicki A; Delcroix M; Ghofrani HA; Hoeper MM; Lang IM; Mayer E; Pepke-Zaba J; Perchenet L; Morganti A; Simonneau G; Rubin LJ;
J Am Coll Cardiol; 2008 Dec; 52(25):2127-34. PubMed ID: 19095129
[TBL] [Abstract][Full Text] [Related]
3. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension.
Hoeper MM; Kramm T; Wilkens H; Schulze C; Schäfers HJ; Welte T; Mayer E
Chest; 2005 Oct; 128(4):2363-7. PubMed ID: 16236895
[TBL] [Abstract][Full Text] [Related]
4. Bosentan for chronic thromboembolic pulmonary hypertension.
Confalonieri M; Kodric M; Longo C; Vassallo FG
Expert Rev Cardiovasc Ther; 2009 Dec; 7(12):1503-12. PubMed ID: 19954311
[TBL] [Abstract][Full Text] [Related]
5. Venous endotelin-1 (ET-1) and brain natriuretic peptide (BNP) plasma levels during 6-month bosentan treatment for pulmonary arterial hypertension.
Vizza CD; Letizia C; Petramala L; Badagliacca R; Poscia R; Zepponi E; Crescenzi E; Nona A; Benedetti G; Ferrante F; Sciomer S; Fedele F
Regul Pept; 2008 Nov; 151(1-3):48-53. PubMed ID: 18796317
[TBL] [Abstract][Full Text] [Related]
6. Cardiopulmonary exercise testing to evaluate the exercise capacity of patients with inoperable chronic thromboembolic pulmonary hypertension: an endothelin receptor antagonist improves the peak PETCO2.
Hirashiki A; Adachi S; Nakano Y; Kono Y; Shimazu S; Shimizu S; Morimoto R; Okumura T; Takeshita K; Yamada S; Murohara T; Kondo T
Life Sci; 2014 Nov; 118(2):397-403. PubMed ID: 24641953
[TBL] [Abstract][Full Text] [Related]
7. No changes in N-terminal pro-brain natriuretic peptide in a longitudinal cohort of patients with systemic sclerosis-associated pulmonary arterial hypertension on therapy with bosentan.
Rotondo C; Praino E; Nivuori M; di Serio F; Lapadula G; Iannone F
Int J Rheum Dis; 2017 Jan; 20(1):90-96. PubMed ID: 26218502
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study.
Hughes RJ; Jais X; Bonderman D; Suntharalingam J; Humbert M; Lang I; Simonneau G; Pepke-Zaba J
Eur Respir J; 2006 Jul; 28(1):138-43. PubMed ID: 16611652
[TBL] [Abstract][Full Text] [Related]
9. Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy.
Seyfarth HJ; Pankau H; Hammerschmidt S; Schauer J; Wirtz H; Winkler J
Chest; 2005 Aug; 128(2):709-13. PubMed ID: 16100158
[TBL] [Abstract][Full Text] [Related]
10. Long-term bosentan in chronic thromboembolic pulmonary hypertension.
Seyfarth HJ; Hammerschmidt S; Pankau H; Winkler J; Wirtz H
Respiration; 2007; 74(3):287-92. PubMed ID: 16699254
[TBL] [Abstract][Full Text] [Related]
11. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension.
McLaughlin VV; Oudiz RJ; Frost A; Tapson VF; Murali S; Channick RN; Badesch DB; Barst RJ; Hsu HH; Rubin LJ
Am J Respir Crit Care Med; 2006 Dec; 174(11):1257-63. PubMed ID: 16946127
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease.
Diller GP; Dimopoulos K; Kaya MG; Harries C; Uebing A; Li W; Koltsida E; Gibbs JS; Gatzoulis MA
Heart; 2007 Aug; 93(8):974-6. PubMed ID: 17639112
[TBL] [Abstract][Full Text] [Related]
13. Secondary pulmonary arterial hypertension: treated with endothelin receptor blockade.
Sharma S; Kashour T; Philipp R
Tex Heart Inst J; 2005; 32(3):405-10. PubMed ID: 16392231
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of bosentan for pulmonary arterial hypertension in adults with congenital heart disease.
Monfredi O; Griffiths L; Clarke B; Mahadevan VS
Am J Cardiol; 2011 Nov; 108(10):1483-8. PubMed ID: 21943933
[TBL] [Abstract][Full Text] [Related]
15. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.
Channick RN; Simonneau G; Sitbon O; Robbins IM; Frost A; Tapson VF; Badesch DB; Roux S; Rainisio M; Bodin F; Rubin LJ
Lancet; 2001 Oct; 358(9288):1119-23. PubMed ID: 11597664
[TBL] [Abstract][Full Text] [Related]
16. Bosentan therapy for pulmonary arterial hypertension.
Rubin LJ; Badesch DB; Barst RJ; Galie N; Black CM; Keogh A; Pulido T; Frost A; Roux S; Leconte I; Landzberg M; Simonneau G
N Engl J Med; 2002 Mar; 346(12):896-903. PubMed ID: 11907289
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of bosentan in a small cohort of adult patients with pulmonary arterial hypertension related to congenital heart disease.
Benza RL; Rayburn BK; Tallaj JA; Coffey CS; Pinderski LJ; Pamoukian SV; Bourge RC
Chest; 2006 Apr; 129(4):1009-15. PubMed ID: 16608951
[TBL] [Abstract][Full Text] [Related]
18. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial.
Galiè N; Rubin Lj; Hoeper M; Jansa P; Al-Hiti H; Meyer G; Chiossi E; Kusic-Pajic A; Simonneau G
Lancet; 2008 Jun; 371(9630):2093-100. PubMed ID: 18572079
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome and effects of oral bosentan therapy in Taiwanese patients with advanced idiopathic pulmonary arterial hypertension.
Hsu HH; Chen JS; Chen RJ; Ko WJ; Kuo SW; Wu ET; Wu MH; Wang JK; Lee YC
Respir Med; 2007 Jul; 101(7):1556-62. PubMed ID: 17223329
[TBL] [Abstract][Full Text] [Related]
20. Bosentan therapy for chronic thromboembolic pulmonary hypertension. A national open label study assessing the effect of Bosentan on haemodynamics, exercise capacity, quality of life, safety and tolerability in patients with chronic thromboembolic pulmonary hypertension (BOCTEPH-Study).
Ulrich S; Speich R; Domenighetti G; Geiser T; Aubert JD; Rochat T; Huber L; Treder U; Fischler M
Swiss Med Wkly; 2007 Oct; 137(41-42):573-80. PubMed ID: 17990150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
